ARQL ArQule, Inc.

1.57
+0.08  (5.37%)
Previous Close 1.49
Open 1.50
Price To book 3.52
Market Cap 111.66M
Shares 71,118,000
Volume 130,463
Short Ratio 2.99
Av. Daily Volume 122,456

SEC filingsSee all SEC filings

  1. 8-K - Current report 17519183
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161976884
  3. 8-K - Current report 161976595
  4. 8-K - Current report 161951413
  5. 424B5 - Prospectus [Rule 424(b)(5)] 161951409

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment to be completed soon - as of November 2016.
ARQ 087
intrahepatic cholangiocarcinoma (iCCA)
Phase 3 SPA agreed upon. Dosage reduced following recommendation from DMC. Top-line data due 1Q 2017.
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer

Latest News

  1. ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher
  2. ARQULE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
  3. ETFs with exposure to ArQule, Inc. : December 21, 2016
  4. How ArQule, Inc. (ARQL) Stacks Up Against Its Peers
  5. Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology Annual Meeting
  6. Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
  7. ARQULE INC Financials
  8. Could Trump Tax Cut Plans, Republican Congress Spur Biotech M&A?
  9. ArQule, Inc. :ARQL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016
  10. Edited Transcript of ARQL earnings conference call or presentation 7-Nov-16 2:00pm GMT
  11. ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  12. Q3 2016 ArQule Inc Earnings Release - Before Market Open
  13. ArQule Reports Third Quarter 2016 Financial Results
  14. Advancements in ArQule’s Proprietary Pipeline to be Highlighted at the 2016 American Society of Hematology Annual Meeting
  15. ARQULE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  16. ArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28, 2016
  17. ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016
  18. Can The Uptrend Continue for ArQule (ARQL)?
  19. ArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28, 2016
  20. ETF’s with exposure to ArQule, Inc. : September 19, 2016

SEC Filings

  1. 8-K - Current report 17519183
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161976884
  3. 8-K - Current report 161976595
  4. 8-K - Current report 161951413
  5. 424B5 - Prospectus [Rule 424(b)(5)] 161951409
  6. EFFECT - Notice of Effectiveness 161923842
  7. CORRESP [Cover] - Correspondence
  8. S-3/A [Amend] - Registration statement under Securities Act of 1933 161900164
  9. CORRESP [Cover] - Correspondence
  10. UPLOAD [Cover] - SEC-generated letter